Literature DB >> 17412726

Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study.

J D Cavallo1, D Hocquet, P Plesiat, R Fabre, M Roussel-Delvallez.   

Abstract

OBJECTIVES: Pseudomonas aeruginosa is a major causative agent of hospital infections. The purpose of this study was to determine the antibiotic susceptibility of P. aeruginosa in a French multicentre study and to investigate the mechanisms of beta-lactam resistance.
METHODS: Four hundred and fifty non-repetitive strains of P. aeruginosa were collected in 15 French university hospitals in 2004. MICs of antibiotics were measured by agar dilution methods. For all the strains with MICs of ticarcillin >16 mg/L, detection and identification of the beta-lactamases, quantitative determination of cephalosporinase and overproduction of the MexAB-OprM efflux pump were evaluated.
RESULTS: The percentages of susceptible isolates were as follows: ticarcillin, 62%; ticarcillin + clavulanic acid, 61%; piperacillin, 78%; piperacillin + tazobactam, 80% (MICs <or= 16 mg/L); aztreonam, 50%; ceftazidime, 78%; cefepime, 64%; imipenem, 83%; tobramycin, 80% (MICs <or= 4 mg/L); amikacin, 86% (MIC <or= 8 mg/L); ciprofloxacin, 68%; and levofloxacin, 57% (MICs <or= 1 mg/L). Decreased susceptibility to imipenem was linked in two cases to VIM-type carbapenemase production. Overexpression of the AmpC cephalosporinase, production of acquired beta-lactamases including SHV2a extended-spectrum beta-lactamase and overproduction of the MexAB-OprM efflux pump were present in 16.9%, 6.5% and 22.3% of the strains, respectively.
CONCLUSIONS: In the last decade, the overall susceptibility of P. aeruginosa hospital isolates to antibiotics has remained quite stable in France. However, the emergence of extended-spectrum beta-lactamases and carbapenemases in different locations is a matter of concern.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412726     DOI: 10.1093/jac/dkm076

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Strain-tailored double-disk synergy test detects extended-spectrum oxacillinases in Pseudomonas aeruginosa.

Authors:  Didier Hocquet; Barbara Dehecq; Xavier Bertrand; Patrick Plésiat
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

Review 2.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

3.  Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.

Authors:  Bartolomé Moyá; Alejandro Beceiro; Gabriel Cabot; Carlos Juan; Laura Zamorano; Sebastián Alberti; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

4.  Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.

Authors:  Didier Hocquet; Patrick Plésiat; Barbara Dehecq; Pierre Mariotte; Daniel Talon; Xavier Bertrand
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

5.  Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.

Authors:  Bartolome Moya; Laura Zamorano; Carlos Juan; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

6.  Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.

Authors:  Carlos Juan; Laura Zamorano; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

7.  Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase.

Authors:  C Peña; C Suarez; F Tubau; C Juan; B Moya; M A Dominguez; A Oliver; M Pujol; J Ariza
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

8.  Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients.

Authors:  Laurence Armand-Lefèvre; Cécile Angebault; François Barbier; Emilie Hamelet; Gilles Defrance; Etienne Ruppé; Régis Bronchard; Raphaël Lepeule; Jean-Christophe Lucet; Assiya El Mniai; Michel Wolff; Philippe Montravers; Patrick Plésiat; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

9.  Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.

Authors:  O Gutiérrez; C Juan; E Cercenado; F Navarro; E Bouza; P Coll; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

10.  Pseudomonas aeruginosa: resistance to the max.

Authors:  Keith Poole
Journal:  Front Microbiol       Date:  2011-04-05       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.